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COVID-19 is a spectrum of clinical symptoms in humans caused by infection with 
SARS-CoV-2, a recently emerged coronavirus that has rapidly caused a pandemic. 
Coalescence of a second wave of this virus with seasonal respiratory viruses, 
particularly influenza virus is a possible global health concern. To investigate this, 
transgenic mice expressing the human ACE2 receptor driven by the epithelial cell 
cytokeratin-18 gene promoter (K18-hACE2) were first infected with IAV followed by 
SARS-CoV-2. The host response and effect on virus biology was compared to K18-
hACE2 mice infected with IAV or SARS-CoV-2 only. Infection of mice with each 
individual virus resulted in a disease phenotype compared to control mice. Although 
SARS-CoV-2 RNA synthesis appeared significantly reduced in the sequentially 
infected mice, these mice had a more rapid weight loss, more severe lung damage 
and a prolongation of the innate response compared to singly infected or control mice. 
The sequential infection also exacerbated the extrapulmonary manifestations 
associated with SARS-CoV-2. This included a more severe encephalitis. Taken 
together, the data suggest that the concept of ‘twinfection’ is deleterious and mitigation 
steps should be instituted as part of a comprehensive public health response to the 
COVID-19 pandemic. 
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Introduction 
Coronaviruses were once described as the backwater of virology but the last two 
decades have seen the emergence of three major coronavirus threats 1. First, the 
emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in China 
in 2003. Second, Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi 
Arabia in 2012 and now SARS-CoV-2 originating in China in 2019. Whilst SARS-CoV 
was eradicated both MERS-CoV and SARS-CoV-2 represent current ongoing health 
threats, and a greater understanding is required to develop robust interventions for 
future emergent coronaviruses. Coronaviruses share similar genome architectures 
and disease profiles and generally cause respiratory and gastrointestinal illnesses 1. 
However, some animal/avian coronaviruses can also cause demyelination and 
nephritis. The sheer scale of the COVID-19 outbreak has highlighted hitherto 
unexpected aspects of coronavirus infection in humans, including long term disease 
complications once the virus has been cleared.  
 
Infection of humans with SARS-CoV-2 results in a range of clinical symptoms, from 
asymptomatic to severe infection and subsequent death in both at risk individuals but 
also a small proportion of otherwise healthy individuals across all age groups. Severe 
infection in humans is typified by cytokine storms 2,3, pneumonia and kidney failure. 
Examination of post-mortem tissue reveals a disconnect between viral replication and 
immune pathology 4. A range of other symptoms also occur, including gastrointestinal 
symptoms such as vomiting, diarrhoea, abdominal pain and loss of appetite. A small 
number of patients present without any overt respiratory symptoms at all. Typically, 
patients with severe COVID-19 present to hospital in the second week of illness. There 
is often a precipitous decline in respiratory function, without necessarily much in the 
way of “air hunger.” Once intubated, these patients have unique ventilatory 
characteristics, where they can be ventilated with relatively low inspired oxygen 
concentrations but need high positive end expiratory pressures. 
 
Respiratory infections in humans and animals can also be synergistic in which an initial 
infection can exacerbate a secondary infection or vice versa. When multiple 
pathogens are in circulation at the same time this can lead to cooperative or 
competitive forms of pathogen-pathogen interactions 5. This was evident during the 
1918 Spanish influenza A virus outbreak (IAV) where secondary bacterial pneumonia 
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was thought to be a leading cause of death 6. Co-infections in other viral diseases, 
such as patients with Ebola virus disease, have also been shown to contribute to the 
host response and outcome 7. As many countries move from a period of lock down 
from the summer months the incidence of SARS-CoV-2 infection is likely to increase 
in frequency as is currently being witnessed in several European countries. The onset 
of winter in the Northern Hemisphere has coincided with a second and possible 
seasonal wave of SARS-CoV-2 that is likely to be co-incident with other respiratory 
pathogens. In most temperate sites the usual seasonal respiratory coronavirus peak 
occurs either slightly before or simultaneously with the IAV and influenza B virus 
peaks, and this may occur with SARS-CoV-2. Generally, human coronaviruses display 
winter seasonality between the months of December and April and are not detected 
in summer months 8. This is a similar pattern seen with influenza viruses. Between 11 
to 41% of patients with normal human coronavirus infection test positive for other 
respiratory viruses 8. Our hypothesis was that co-circulation of SARS-CoV-2 and IAV 
could lead to co-infection, and if so, this may exacerbate clinical disease and 
potentially outcome. 
 
Previous work has shown co-infections are present in patients with severe coronavirus 
infection. For SARS-CoV co-circulation of human metapneumovirus was reported in 
an outbreak in Hong Kong. However, data suggested that outcomes were not different 
between patients with identified co-infections and those with SARS-CoV alone 9. For 
MERS-CoV, four cases of co-infection with influenza A virus were described, and 
although no data was presented on the severity of symptoms this sample size would 
be too small to generate any meaningful conclusions 10. Post-mortem studies from 
patients with COVID-19 in Beijing (n=85) identified IAV in 10% of patients, influenza B 
virus in 5% of patients and 3% of patients had RSV, but the absence of a carefully 
selected control arm prohibits conclusions to be drawn 11. Recently there have been 
several case reports of coinfections with IAV and SARS-CoV-2 in humans with severe 
outcomes 12-17 with one study from the UK reporting that patients with a coinfection 
exhibiting a ~6 times higher risk of death18. Whilst this suggests that coinfection is 
synergistic, this study also found that the risk of testing positive for SARS-CoV-2 was 
68% lower among individuals who were positive for IAV infection, implying that the two 
viruses may competitively exclude each other18. 
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Whilst the analysis of post-mortem tissue is extremely informative in what may have 
led to severe coronavirus infection and death, the analysis of the disease in severe 
(but living cases) is naturally restricted by what tissues can be sampled (e.g. blood, 
nasopharyngeal swabs and bronchial alveolar lavages). Therefore, animal models of 
COVID-19 present critical tools to fill knowledge gaps for the disease in humans and 
for screening therapeutic or prophylactic interventions. Compatibility with a more 
extensive longitudinal tissue sampling strategy and a controlled nature of infection are 
key advantages of animal models 19. Studies in an experimental mouse model of 
SARS-CoV showed that co-infection of a respiratory bacterium exacerbated 
pneumonia 20. Different animal species can be infected with wild-type SARS-CoV-2 to 
serve as models of COVID-19 and these include mice, hamsters, ferrets, rhesus 
macaques and cynomolgus macaques. The K18-hACE2 transgenic (K18-hACE2) 
mouse, where hACE2 expression is driven by the epithelial cell cytokeratin-18 (K18) 
promoter, was developed to study SARS-CoV pathogenesis21. This mouse is now 
being used as a model that mirrors many features of severe COVID-19 infection in 
humans to develop understanding of the mechanistic basis of lung disease and to test 
pharmacological interventions22,23. 
 
With the approaching flu season in the Northern hemisphere concomitant with a 
second wave of SARS-CoV-2 infections there is an obvious public health concern 
about the possibility of enhanced morbidity and mortality in co-infected individuals. 
The aim of this work was to use an established pre-clinical model of COVID-19 to 
study the consequences of co-infection with SARS-CoV-2 and IAV, defining the 
associated clinical, pathological and transcriptomic signatures.   
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Sequential infection with IAV and SARS-CoV-2 leads to enhanced disease. 
 
To assess how co-infection with influenza virus affected COVID-19, the established 
K18-hACE2 mouse model of SARS-CoV-2 was utilised 21. We sued a clinical isolate 
of SARS-CoV-2 (strain hCoV-19/England/Liverpool_REMRQ0001/2020)24. 
Importantly, sequence of the virus stock demonstrated that this isolate did not contain 
the recently observed deletion or mutations of the furin cleavage site in the S protein 
25. A schematic of the experimental design is shown in Fig. 1A. Four groups of mice (n 
= 8 per group) were used. At day 0, two groups were inoculated intranasally with 102 
PFU IAV (strain A/X31) and two groups with PBS. After three days, two groups were 
inoculated intranasally with 104 PFU of SARS-CoV-2. This generated four 
experimental groups: Control, IAV only, SARS-CoV-2 and IAV + SARS-CoV-2 only 
(Fig. 1B). Control mice maintained their body weight throughout. Mice infected with 
IAV displayed a typical pattern of weight loss, reaching a nadir (mean 17% loss) at 7 
dpi before starting recovery. SARS-CoV-2-infected animals started to lose weight at 
day 7 (4 dpi) and carried on losing weight up to day 10 (mean 15% loss). Mice infected 
with IAV then SARS-CoV-2 had a significantly-accelerated weight loss as compared 
with IAV-infected mice from day 4 which was most severe at day 6 (mean 19%), 
followed by a recovery to day 8 (mean 14% loss) before losing weight again (mean 
17% loss) (Fig. 2A). As well as accelerated weight loss, IAV + SARS-CoV-2-infected 
mice exhibited more severe respiratory symptoms and a significantly more rapid 
mortality, (assessed by a humane endpoint of 20% weight loss) as compared with 
mice infected with either virus alone (Fig. 2B). 
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Figure 1: (A) Schematic diagram of the experimental design for infection of K18-hACE2 mice 
sequentially with IAV strain A/X31 and SARS-CoV-2 (hCoV-
19/England/Liverpool_REMRQ0001/2020). B: Table showing exposures given to the four 
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Figure 2: Co-infection with IAV and SARS-CoV-2 leads to enhanced weight loss and 
more rapid mortality. K18-hACE2 mice were challenged intranasally with IAV strain X31 (102 
pfu) and 3 days later with 104 PFU SARS-CoV-2 (A) Mice were monitored for weight loss at 
indicated time-points. (n = 8). Data represent the mean value ± SEM. Comparisons were made 
using a repeated-measures two-way ANOVA (Bonferroni post-test). (B) Survival was 
assessed at indicated time points (n = 8). Comparisons were made using log-rank (Mantel-
Cox) test.  ** represents P < 0.01; *** represents P < 0.001 
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Coinfection of SARS-COV-2 and IAV results in reduced SARS-COV-2 viral load 
at day 6 but not day 10 post IAV 
In order to determine whether the coinfection of SARS-CoV-2 and IAV was 
cooperative or competitive total RNA was extracted from the lungs of the K18-hACE2 
mice and viral loads were quantified using qRT-PCR. At day 6 (3 dpi), the SARS-CoV-
2 infected mice exhibited 10,000-fold higher levels of viral load than at day 10 (7 dpi) 
(mean 6 x 1012 vs 2.8 x 108 copies of N/µg of RNA) indicating that peak viral replication 
takes place before the onset of symptoms at 4 dpi (Fig, 3A). At this timepoint the mice 
infected with SARS-CoV-2 alone displayed significantly higher levels of viral RNA than 
the mice coinfected with IAV and SARS-COoV-2 (mean 6 x 1012 vs ~2 x 1 09 copies 
of N/µg of RNA) (Fig. 3A). However, by day 10 the coinfected and singly infected mice 
exhibited nearly identical levels of SARS-CoV-2 RNA (mean 2 x 108 vs 8.1 x 108 copies 
of N/µg of RNA) (Fig. 3A). Conversely, at day 6, the mice infected with IAV alone 
showed similar levels of IAV RNA compared to the coinfected mice (mean 1.3 x 107 
vs 1 x 107 copies of M/µg of RNA) and by day 10 both the singly infected mice and 
coinfected mice did not display any detectable IAV RNA, demonstrating similar levels 
of IAV clearance (Fig. 3C). In order to investigate viral replication qPCR was employed 
to quantify viral subgenomic mRNA (sgRNA) transcripts. Unlike viral genomes, 
sgRNAs are not incorporated into virions, and can therefore be utilised to measure 
active virus infection. The amount of sgRNA in the SARS-CoV-2 infected mice was 
concomitant with the viral load, appearing to be 100-fold higher at day 6 (3dpi) than 
day 10 (7dpi) (mean 6.2 x 106 vs 5.4 x 104 copies of E sgRNA/µg of RNA) (Fig. 3B). 
Similarly, the amount of sgRNA was significantly lower in the coinfected mice 
compared to the SARS-CoV-2 singly infected mice (mean 6.2 x 106 vs 1.7 x 104 copies 
of E sgRNA/µg of RNA) however, by day 10 (7dpi) both coinfected and singly infected 
mice displayed similar levels of sgRNA (mean 5.4 x 104 vs 3.5 x 105 copies of E 
sgRNA/µg of RNA) (Fig. 3C). 
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Figure 3: Viral loads and SARS-CoV-2 sgRNA levels in single and co-infected mice.  
K18-hACE2 mice were challenged intranasally with IAV strain X31 (102 pfu) and 3 days later 
with 104  PFU SARS-CoV2 (n = 4). RNA extracted from lungs was analysed for virus levels by 
qRT-PCR. Assays were normalised relative to levels of 18S RNA.  Data for individual animals 
are shown with the median value represented by a black line (A) SARS-CoV-2 viral load was 
determined using qRT-PCR for the N gene. (B) Levels of SARS-CoV-2 sub-genomic RNA 
(sgRNA) for the E gene. (C) IAV load was determined using RT-PCR for the M gene. 
Comparisons were made using two-way ANOVA (Bonferroni post-test). * represents p < 0.05 
 
Co-infection leads to complementary and enhanced pathological processes 
  
Transgenic mice carrying the human ACE2 receptor under the control of the keratin 
18 promoter (K18-hACE2) have been reported as a suitable COVID-19 model 22. As 
a basis for the assessment of the effect of IAV and SARS-CoV-2 in these mice, a 
histological examination of major organs/tissues was performed. This confirmed that 
the transgenic approach had not resulted in phenotypic changes. Comparative 
staining of wild type and transgenic mice for ACE2, using an antibody against human 
ACE2 that also cross-reacted with mouse ACE2, also confirmed that transgenesis had 
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not altered the ACE2 expression pattern (respiratory epithelial cells and very rare type 
II pneumocytes (Supplementary Fig. 1 A, B), endothelial cells in brain capillaries (Fig. 
7 A2, A3) and liver sinusoids, renal tubular epithelial cells). The expression was not 
affected by viral infection (Supplemental Fig. C-F; Fig. 7 B3, C3).  
At 6 days post IAV infection, the transgenic mice exhibited the pulmonary 
changes typically observed in mice after IAV X31 infection at this time point. We 
observed epithelial cell degeneration and necrosis in several bronchioles which also 
contained debris in the lumen (Figs. 4 B, 5B). There were occasional small focal 
peribronchial areas where alveoli also exhibited necrotic cells (Fig. 4 B). IAV antigen 
was found in epithelial cells in bronchi and bronchioles, in type I and II pneumocyte in 
affected alveoli, and in few randomly distributed individual type II pneumocytes (data 
not shown). Vessels showed evidence of lymphocyte recruitment, vasculitis and 
perivascular lymphocyte infiltration. Comparative assessment of the lungs in wild type 
mice at the same time point post infection confirmed that the genetic manipulation 
indeed had no effect on the response of mice to IAV infection (data not shown). At the 
comparative time point, SARS-CoV-2 single infection (day 6, 3 dpi) was associated 
with mild changes, represented by a mild increase in interstitial cellularity, evidence of 
type II pneumocyte activation (Fig. 4C, 5A), occasional desquamated alveolar 
macrophages/type II pneumocytes and single erythrocytes in alveolar lumina, and a 
multifocal, predominantly perivascular mononuclear infiltration with recruitment of 
leukocytes into vascular walls (vasculitis) (Fig. 4 D). Viral antigen was found in 
multifocal patches of individual to large groups of alveoli, randomly distributed 
throughout the parenchyma (Fig. 5A2). Viral antigen was seen in type I and type II 
pneumocytes and in endothelial cells in capillaries and small vessels in septa (Fig. 
5A3). However, viral antigen was not detected within bronchiolar epithelial cells (Fig. 
5A2). Double infection at this time point, i.e. 6 days after IAV infection and 3 days after 
SARS-CoV-2 infection was associated with histological changes almost identical to 
those induced by IAV, although they appeared to be slightly more extensive (Fig4 E, 
F). IAV antigen expression had a distribution and extent similar to that seen in single 
IAV infection at the same time point. Viral antigen was found in epithelial cells in 
bronchi and bronchioles, in type I and II penumocytes in affected alveoli, and in few 
randomly distributed individual type II pneumocytes (Fig. 5B2). SARS-CoV-2 
expression was less intense than in SARS-CoV-2-only infected mice. Viral antigen 
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was observed in random individual or small groups of alveoli (Fig. 5B3), in type I and 
II pneumocytes and vascular endothelial cells (Fig. 5B3 inset). 
 
Four days later, at the endpoint of the experiment, i.e. at 10 days after IAV infection 
and 7 days of SARS-CoV-2 infection, the histopathological features had changed. 
Single IAV infection had by then almost entirely resolved, however, the lungs exhibited 
changes consistent with a regenerative process, i.e. mild to moderate hyperplasia of 
the bronchiolar epithelium with adjacent multifocal respiratory epithelial 
metaplasia/type II pneumocyte hyperplasia, together with mild to moderate 
lymphocyte dominated perivascular infiltration (Fig. 6A). Interestingly, the hyperplastic 
epithelium was found to lack ACE2 expression (Supplemental Fig. 1 E). At this stage, 
the effect of SARS-CoV-2 infection was more evident. Single infection had resulted in 
multifocal areas with distinct type II pneumocyte activation and syncytial cell formation 
(Fig. 6B), with mild mononuclear infiltration, and mild to moderate lymphocyte-
dominated vasculitis and perivascular infiltration. There were also a few focal areas of 
mild desquamative pneumonia with intra-alveolar macrophages/type II pneumocytes, 
oedema and fibrin deposition. These changes were also observed in the double 
infected mice (Fig. 6C-F), where they were generally more pronounced (Fig. Lungs 
6D-F) and present alongside equally pronounced regenerative changes attributable to 
IAV infection (moderate hyperplasia of the bronchiolar epithelium with adjacent 
multifocal respiratory epithelial metaplasia/type II pneumocyte hyperplasia; Fig. 6C). 
  
In three of the four single SARS-CoV-infected and two of the four double infected mice 
at the later time point (7 days post SARS-CoV-2 infection), we observed a mild or 
moderate non-suppurative meningoencephalitis mainly affecting the midbrain and 
brainstem (Fig. 7B, C). This was more severe in the double infected mice, where the 
perivascular infiltrates contained degenerate leukocytes and appeared to be 
associated with focal loss of integrity of the endothelial cell layer (Fig. 7C2, 3).   
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Figure 4: Lungs, hACE transgenic mice, after mock infection or at day 6 post infection with 
IAV and day 3 post infection with SARS-CoV-2 in single and double infections. A. Mock 
infected control animal. Normal lung. B. IAV-infected animal; 6 dpi. Bronchioles (B) exhibit 
necrosis (arrowhead) of a variable amount of epithelial cells and (*). The parenchyma adjacent 
to affected bronchioles often exhibits individual alveoli with necrotic epithelial cells (arrow). C, 
D. Sars-CoV-2-infected animal; 3 dpi. The parenchyma exhibits multifocal activation of type II 
pneumocytes (C: arrowheads), and there is evidence of vasculitis, represented by leukocyte 
infiltration of vessel (V) walls (D: arrowheads) and perivascular infiltrates (arrows). E, F. IAV 
(6 dpi) and Sars-CoV-2 (3 dpi) double infection. The IAV-associated changes, with necrosis 
of bronchiolar epithelial cells (E: arrowhead), debris in bronchiolar lumina (*), focal necrosis of 
alveolar epithelial cells (arrows) as well some activation and hyperplasia of type II 
pneumocytes (F: arrowheads), dominate the histological picture. B – bronchiole; V – vessel. 
HE stain; Bars = 20 µm. 
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Figure 5: Lungs, hACE transgenic mice, at day 6 post infection with IAV and day 3 post 
infection with SARS-CoV-2 in single and double infections. A. Sars-CoV-2-infected animal; 3 
dpi. A1. There is mild perivascular mononuclear infiltration (V: vessel), and the parenchyma 
exhibits mild multifocal activation of type II pneumocytes (inset). A2, A3. Staining for SARS-
CoV-2 reveals random multifocal areas of SARS-CoV-2 infection, affecting both individual 
alveoli (A2: arrowheads) and large parenchymal areas. Viral antigen expression is seen in 
type I pneumocytes (A2: arrowheads), type II pneumocytes (A2: arrows) and vascular 
endothelial cells (A2: small, short arrows). B. IAV (6 dpi) and Sars-CoV-2 (3 dpi) double 
infection. B1. The IAV-associated changes dominate (see also Fig. 4E). This is confirmed by 
staining for IAV antigen expression (B2). IAV antigen is detected in bronchiolar epithelial cells 
(arrow), occasional type I pneumocytes (arrowhead) and disseminated type II pneumocytes 
(short, small arrows). B3. SARS-CoV-2 infection is seen in areas not affected by IAV- induced 
changes (B: bronchioles with IAV changes) and mainly in individual alveoli where both type I 
and type II pneumocytes are found to express viral antigen (inset). B – bronchiole; V - vessel. 
Immunohistology, hematoxylin counterstain. Bars = 20 µm. 
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Figure 6: Lungs, hACE transgenic mice, at day 10 post infection with IAV and day 7 post 
infection with SARS-CoV-2 in single and double infections. A. IAV-infected animal; 10 dpi. 
Bronchioles (B) exhibit epithelial cell hyperplasia (arrowhead) and there is type II pneumocyte 
hyperplasia (*) in the adjacent parenchyma. Vessels exhibit variably intense lymphocyte-
dominated perivascular infiltrates (arrows). B. Sars-CoV-2-infected animal; 7 dpi. There are 
abundant activated type II pneumocytes which also show syncytia formation (arrowheads). C-
F. IAV (10 dpi) and Sars-CoV-2 (7 dpi) double infection. C. There are abundant changes 
consistent with those seen in single IAV-infected mice, i.e. epithelial cell hyperplasia in 
bronchioles (B), multifocal type II pneumocyte hyperplasia (*), and perivascular (V: vessel) 
lymphocyte dominated infiltrates (arrow). D-F. Changes attributable to SARS-CoV-2 infection. 
These comprise type II pneumocyte activation and syncytia formation (D: arrowheads) and 
desquamative pneumonia (E, F), with desquamation of alveolar macrophages/type II 
pneumocytes (arrows) and type II pneumocyte activation (arrowheads). In more severe cases, 
alveoli occasionally contain fibrin and hyaline membranes (*). HE stain; Bars = 20 µm. 
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Figure 7: Brain, hypothalamus, mock infected wild type and hACE transgenic mice, SARS-
CoV-2 infected hACE transgenic mice at day 7 post infection, and IAV (day 10 post infection) 
and SARS-CoV-2 (day 7 post infection) double infected hACE transgenic mice. A. Mock 
infected control animals. A1. hACE2 transgenic mouse, unaltered hypothalamus. A1, A2. 
ACE2 expression in capillary endothelial cells in hACE2 transgenic mouse (A2) and wildtype 
mouse (A3). B. SARS-CoV-2 infected hACE transgenic mouse. B1. Vessels in the 
leptomeninx (arrow) and in the brain parenchyma (arrowhead) exhibit mild perivascular 
mononuclear infiltrations, consistent with mild non-suppurative meningoencephalitis. B2. 
Higher magnification highlighting the one-layered perivascular infiltrate (arrow). B3. 
Endothelial ACE2 staining shows an intact endothelial layer (arrowheads) also in areas of 
perivascular infiltration (arrow). C. IAV and SARS-CoV-2 double infected hACE transgenic 
mouse. The perivascular mononuclear infiltrate is slightly more intense than in the SARS-CoV-
2 single infected mouse (C1: arrows), consistent with a mild to moderate non-suppurative 
meningoencephalitis. Among the perivascular infiltrate are several degenerate cells (C2: 
arrowheads). C3. Endothelial ACE2 expression (arrowheads) is lost in areas of more intense 
infiltration (arrows). HE stain and immunohistology, hematoxylin counterstain. Bars = 20 µm. 
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Distinct transcriptional signatures are associated with infection 
The transcriptional profile of lung samples can provide a window on the host response 
to infection for a respiratory pathogen. Therefore, lung samples were taken at Day 6 
and Day 10 post IAV infection from all four groups of mice (Fig. 1B). Total RNA was 
purified from cells and both host and viral mRNA (and genomic RNA in the case of 
SARS-CoV-2) were sequenced using the Oxford Nanopore oligo-dT cDNA synthesis 
approach to identify and quantify mRNA. A multiplex of 5-10 sequencing libraries were 
loaded onto a flow cell and sequenced on an Oxford Nanopore GridION for up to 72 
hours. 
 
Genes were counted against the Mus musculus annotated genome using Salmon 26. 
Gene counts were normalised using the edgeR package before identifying 
differentially expressed genes using the transcription profile from mock infected mice 
as the control profile. A total of 970 differentially expressed gene transcripts were 
observed in comparison to mock infected animals out of a total of 3495 gene 
transcripts identified. Principle component analysis (PCA) revealed overlapping 
transcriptional profiles between infection groups (Fig. 8A). Overlapping signatures 
were likely to be indicative of the non-specific anti-viral response. Contrast matrices 
were made between mice that were coinfected versus mice that were mock infected 
and mice that were singly infected (Table 1). The transcriptomic profile in mice 10 days 
post infection with IAV showed overlap with the healthy controls, consistent with 
resolution of infection and regeneration seen in the pathology (Supplementary Fig 2). 
The data indicated that coinfection at day 10 versus IAV day 10 had more differences 
with 36 gene transcripts at higher abundance, highlighted in the top 75 differentially 
expressed genes (Fig. 8B). 
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Table 1: Number off differentially expressed genes with an FDR value less than 0.05 and a log2 
fold change more than 2 and less than -2 compared to mock infected mice. Coinfection day 6 and 
day 10 were compared to day 6 and 10 of individual IAV and SARS-CoV-2 infection. 
 IAV Day 6 IAV Day 
10 
SARS-Cov-
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Figure 8: RNA sequencing analysis from hACE2 mice lung homogenates from mice infected 
with either IAV only, SARS-CoV-2 only or IAV and SARS-CoV-2 (n=4-5). A. Principle component 
analysis performed for 29 samples with log2 transformed counts per million (cpm). B. The top 75 
differentially expressed gene transcripts across 4 groups are shown. C. Volcano plots comparing 
differentially expressed genes from each infection group vs mock infected. The horizontal dashed line 
is representative of a q-value <0.05, and the vertical dashed line is representative of a log2 fold-change 
of 2. Significant differentially expressed gene transcripts are marked as red.  
 
Gene ontology analysis of gene transcripts that were significantly different in 
abundance at all time points revealed enrichment of gene clusters involved in the 
innate immune response, immune system regulation and cellular response to cytokine 
stimulus, interferon beta and interferon gamma (supplementary Fig. 4). The 
differentially expressed gene transcripts between coinfection day 10 versus IAV day 
10 were associated with interferon responses according to biological process terms 
(supplementary Fig. 5). 
 
Interferon and cytokine responses are upregulated in response to infection, and 
maintained in coinfection 
Following gene ontology analysis, gene transcripts were grouped by biological 
process terms and presented as heatmaps to allow for direct comparison of their 
abundance across the experimental groups. SARS-CoV-2 infection resulted in the 
increased abundance of gene transcripts involved in the interferon and cytokine 
signalling pathways. When mice were infected with both SARS-CoV-2 and IAV, certain 
gene transcripts within these pathways remained increased in abundance at later time 
points, in comparison to individual IAV infection at day 10 (Fig. 9). These included Ifit1, 
Ifit3, Ifit3b, Isg15, Irf7 and Cxcl10. This suggested a sustained innate/interferon 
response in these animals. 
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In this study, sequential infection with IAV followed by SARS-CoV-2 and led to more 
severe pulmonary disease than infections with IAV or SARS-CoV-2 alone. Following 
IAV infection, mice coinfected with SARS-CoV-2 displayed significantly higher weight 
loss, elevated respiratory distress and more rapid mortality compared to mice infected 
with IAV alone. Transcriptomics analysis revealed that the expression of several 
genes specific to airway epithelial cells such as Scgb3a1, Cfap126, and Cyp2f2 was 
more downregulated in coinfected mice compared to singly infected mice at days 6 
and 10, which is likely indicative of increased lung epithelial cell damage. Interestingly, 
coinfected mice exhibited significantly lower levels of SARS-CoV-2 viral RNA and 
sgRNA at day 6 (3 dpi with SARS-CoV-2) compared to SARS-CoV-2 singly infected 
mice, indicating that, whilst coinfection results in enhanced respiratory symptoms, 
existing IAV infection interferes with infection of SARS-CoV-2 at this time point. These 
findings were recapitulated by analysis and comparison of lung pathology which 
showed that coinfected animals displayed similar yet more pronounced IAV pathology 
compared to IAV singly infected animals but displayed reduced SARS-CoV-2 antigen 
staining compared to SARS-CoV-2 singly infected mice. By day 10, coinfected mice 
Figure 9: Heatmaps showing expression of genes enriched in gene ontology terms. A. Cellular 
response to IFN-(GO:0035458). B. Cellular response to IFN-(GO:0071346). C. Cytokine mediated 
signalling (GO:0019221). D. Negative effects on viral replication (GO:0045071). 
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and SARS-CoV-2 singly infected mice displayed similar levels of viral RNA and 
sgRNA, suggesting that whilst initially inhibited by the presence of IAV, SARS-CoV-2 
was able to overcome this inhibition and achieve unconstrained viral replication. This 
was reflected in the lung transcriptome profile that showed a sustained innate 
response in coinfected animals over the time-period of both infections. Viral 
Interference is a well-documented phenomenon which has previously been reported 
between influenza B viruses (IBV) in a ferret model, in which infection with one IBV 
subtype was able to prevent infection with another subtype when infections were 
separated by 3 days 27. Similar to the observations described herein between IAV and 
SARS-CoV-2, coinfection of antigenically unrelated viruses such as IAV and IBV did 
not confer resistance when challenged within 3 days, but merely delayed the shedding 
of the challenged virus. This delay in shedding likely accounts for the differing times 
at which coinfected animals and SARS-CoV-2 singly infected animals lose weight; 
SARS-CoV-2 singly infected animals exhibit weight loss at 4dpi however, coinfected 
animals begin to recover from IAV infection before succumbing to delayed SARS-CoV-
2 infection. Unlike this study, wherein IAV and SARS-CoV-2 coinfected animals 
exhibited significantly increased weight loss, coinfection with IAV and IBV has been 
reported to delayed viral shedding but did not influence disease severity. 
 
Mathematical modelling and in vitro and in vivo studies have shown that prior infection 
with rhinovirus interferes with IAV infection 5. This interference is mediated by the 
induction of interferon stimulated genes (ISGs) following rhinovirus infection which 
work to suppress IAV. Similarly, infection with IAV results in the activation of the IFN 
response and the upregulation of ISGs which induce an antiviral state which works to 
limit infection 28 and reviewed 29. We propose that it is this response which is active in 
the K-18hACE2 mice 3 days post IAV infection and is responsible for the inhibition of 
the incoming SARS-CoV-2 infection, thus resulting in lower viral load as measured by 
RT-qPCR at day 6. IAV viral load was found to be similar between coinfected and IAV 
singly infected mice, demonstrating that SARS-CoV-2 infection does not interfere with 
prior IAV infection. Similarly, by day 10 (7 dpi SARS-CoV-2) both coinfected and IAV 
singly infected mice were negative for IAV by qPCR, indicating that SARS-CoV-2 
infection does not prolong IAV infection or interfere with the ability of the immune 
system to clear IAV infection. At this stage, the IAV singly infected mice exhibited lung 
pathology associated with regeneration including hyperplasia of the bronchiolar 
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epithelium and respiratory pneumocytes. This regenerative pathology was supported 
by the transcriptomic profiles of the IAV singly infected mice at day 10 which showed 
overlap with the healthy controls. These transcriptomic profiles were characterised by 
the decreased expression of several ISGs including Isg15, Ligp1, Gbp6, Ifi206, Ifitm3 
and Ifit3, compared to day 6. Conversely, while the coinfected mice also displayed 
evidence of epithelial regeneration, they also presented several hallmarks of acute 
lung injury including perivascular infiltration, vasculitis and oedema. This elevated lung 
injury is consistent with the viral loads of SARS-CoV-2 present in these animals at day 
10 and the lung transcriptomic profile which revealed that the coinfected mice 
maintained heightened levels of ISG transcription in addition to several other genes 
associated with cytokine and IFN-γ signalling compared to the IAV singly infected 
mice. 
 
As has recently been reported in studies using K18-hACE2 transgenic mice 23,30, 
pathology revealed brain involvement in some of the SARS-CoV-2 singly infected and 
coinfected mice at day 10 which manifested as non-suppurative meningoencephalitis 
predominantly affecting the midbrain and brainstem.  Previous studies using K18-
hACE2 mice focusing on SARS-CoV have shown that the virus spreads throughout 
the brain around 3 days post intranasal inoculation 21,23,31 however the mechanism of 
entry is unclear as one study reported abundant infection of the olfactory bulb 31 while 
the other showed little involvement 21. Unlike SARS-CoV-2, SARS-CoV has been 
shown to enter the brain earlier at 3dpi but does not elicit notable inflammation in this 
secondary site of infection 31. Interestingly, the coinfected mice displayed more severe 
brain pathology, with perivascular infiltration and epithelial breakdown. The 
mechanism through which co-infection with IAV may enhance SARS-CoV-2 
neurological infection is unclear. While brain infection has been well documented in 
cases of influenza 32-34, this is predominantly limited to neurotropic and highly 
pathogenic strains and occurs via breakdown of the blood brain barrier (BBB) following 
high levels of viremia 33,35. BBB integrity is also reduced by proinflammatory cytokines 
such as IL-6, IL-1β and IFN- γ which disrupt the tight-junctions maintained by brain 
microvascular endothelial cells (reviewed in 36). While the IAV X31 strain used herein 
did not result in brain pathology in singly infected animals, it is possible that the 
increased cytokine response present in coinfected animals further compromised BBB 
integrity and therefore induced enhanced brain pathology.  
.CC-BY 4.0 International licensepreprint (which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for thisthis version posted October 13, 2020. . https://doi.org/10.1101/2020.10.13.334532doi: bioRxiv preprint 
  24
 
No animal model can predict with absolute certainty the consequences of coinfection 
in humans. However, the data presented here may have critical implications for 
development of successful pre-emptive interventions for SARS-CoV-2. Fortunately, 
public health interventions aimed at delaying the transmission of SARS-CoV-2 should 
also provide a consequent reduction in transmission of influenza if they are effectively 
implemented. Moreover, some but not all experimental therapeutics being studied for 
SARS-CoV-2 have also been demonstrated to exhibit activity against influenza. As for 
other viruses for which successful antiviral interventions have been developed, the 
SARS-CoV-2 polymerase has emerged as a strong initial target for small molecule 
inhibitors. Importantly, drugs such as remdesivir and favipiravir that are in various 
stages of development and clinical evaluation for SARS-CoV-2 have a direct or 
metabolite-driven in vitro activity against influenza 37,38, with favipiravir also approved 
for influenza in Japan. Other examples of dual activity against these viruses are 
evident with other small molecule antivirals such as nitazoxanide 39-41 and niclosamide 
42,43, which may present opportunities and/or a basis for prioritisation of candidates for 
clinical evaluation if necessary exposures can be achieved 44,45. Such antiviral 
interventions have potential application in treatment of early infection as well as the 
prophylactic setting. Chemoprevention is a particularly attractive approach as we 
move into winter months, and selection of the right candidates for evaluation may 
provide a benefit for both viruses individually and in coinfection. It should be noted that 
many of the advanced technologies (e.g. broadly neutralising monoclonal antibodies) 
that are being rapidly accelerated through development have explicit specificities that 
provide high potency, but this is likely to preclude activity against viruses other than 
those against which they are directed. The work presented here shows that our 
approach will be an effective pre-clinical platform with which to text therapeutic 
approaches to dealing with co-infection which is pertinent with the approaching flu 
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Cell culture and virus 
Influenza virus A/HKx31 (X31, H3N2) was propagated in the allantoic cavity of 9-day-
old embryonated chicken eggs at 35oC for 72 h. Titres were determined by an 
influenza plaque assay using MDCK cells.  
Vero E6 cells (C1008; African green monkey kidney cells) were obtained from 
Public Health England and maintained in Dulbecco’s minimal essential medium 
(DMEM) containing 10% foetal bovine serum (FBS) and 0.05 mg/mL gentamycin at 
37°C with 5% CO2.  
UK strain of SARS-CoV-2 (hCoV-2/human/Liverpool/REMRQ0001/2020), 
which was cultured from a nasopharyngeal swab from a patient, was passaged a 
further 4 times in Vero E6 cells 24. The fourth passage of virus was cultured MOI of 
0.001 in Vero E6 cells with DMEM containing 4% FBS and 0.05 mg/mL gentamycin at 
37°C with 5% CO2 and was harvested 48 h post inoculation. Virus stocks were stored 
at −80°C. The intracellular viral genome sequence and the titre of virus in the 
supernatant were determined.  Direct RNA sequencing was performed as describe 
previously 25 and an inhouse script was used to check for deletions in the mapped 
reads. The Illumina reads were mapped to the England/2/2020 genome using HISAT 
and the consensus genome was called using an in-house script based on the 
dominant nucleotide at each location on the genome. The sequence has been 
submitted to Genbank, accession number MW041156.  
 
Ethics and clinical information 
The patient from which the virus sample was obtained gave informed consent and was 
recruited under the International Severe Acute Respiratory and emerging Infection 
Consortium (ISARIC) Clinical Characterisation Protocol CCP (https://isaric.net/ccp), 
reviewed and approved by the national research ethics service, Oxford (13/SC/0149). 
Samples from clinical specimens were processed at containment level 3 at the 
University of Liverpool. 
Biosafety. All work was performed in accordance with risk assessments and standard 
operating procedures approved by the University of Liverpool Biohazards Sub-
Committee and by the UK Health and Safety Executive. Work with SARS-CoV-2 was 
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performed at containment level 3 by personnel equipped with respirator airstream 
units with filtered air supply. 
Mice 
Animal work was approved by the local University of Liverpool Animal Welfare and 
Ethical Review Body and performed under UK Home Office Project Licence 
PP4715265.  Mice carrying the human ACE2 gene under the control of the keratin 18 
promoter (K18-hACE2; formally B6.Cg-Tg(K18-ACE2)2Prlmn/J) were used in this 
study were purchased from Jackson Laboratories. Mice were maintained under SPF 
barrier conditions in individually ventilated cages.  
 
Virus infection 
Animals were randomly assigned into multiple cohorts. For IAV infection, mice were 
anaesthetized lightly with KETASET i.m. and inoculated intra-nasally with 102 PFU 
IAV X31 in 50 µl sterile PBS. For SARS-CoV-2 infection, mice were anaesthetized 
lightly with isoflurane and inoculated intra-nasally with 50 µl containing 104 PFU SARS-
CoV-2 in PBS.  They were sacrificed at variable time-points after infection by an 




Tissues were fixed in formal saline for 24 h and routinely paraffin wax embedded. 
Consecutive sections (3-5 µm) were either stained with haematoxylin and eosin (HE) 
or used for immunohistology (IH). IH was performed to detect viral antigens and to 
identify ACE2, using the horseradish peroxidase (HRP) and the avidin biotin complex 
(ABC) method. The following primary antibodies were applied: rabbit anti-human 
ACE2 (Novus Biologicals; clone SN0754; NBP2-67692), goat anti-IAV (Meridian Life 
Sciences Inc., B65141G), following previously published protocols 46-48. and rabbit 
anti-SARS-CoV nucleocapsid protein (Rockland, 200-402-A50). Briefly, after 
deparaffination, sections underwent antigen retrieval in citrate buffer (pH 6.0; Agilent) 
for ACE2 and SARS-CoV NP detection, and Tris/EDTA buffer (pH 9) for IAV for 20 
min at 98 °C, followed by incubation with the primary antibodies (diluted in dilution 
buffer, Agilent; anti-IAV 1:200, anti-ACE2, 1:200 and anti-SARS-CoV 1:3000) and 
overnight at 4⁰C for ACE2 and SARS-CoV and for 1 h at room temperature (RT) for 
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IAV. This was followed by blocking of endogenous peroxidase (peroxidase block, 
Agilent) for 10 min at RT and incubation with the secondary antibodies, 
EnVision+/HRP, Rabbit (Agilent) for ACE2 and SARS-CoV, and rabbit anti-goat 
Ig/HRP (Agilent) for IAV), for 30 min at RT, and EnVision FLEX DAB+ Chromogen in 
Substrate buffer (Agilent) for 10 min at RT, all in an autostainer (Dako). Sections were 
subsequently counterstained with haematoxylin.  
 
 
RNA extraction and DNase treatment 
The upper lobes of the right lung were dissected and homogenised in 1ml of TRIzol 
reagent (Thermofisher) using a Bead Ruptor 24 (Omni International) at 2 meters per 
second for 30 sec. The homogenates were clarified by centrifugation at 12,000xg for 
5 min before full RNA extraction was carried out according to manufacturer’s 
instructions. RNA was quantified and quality assessed using a Nanodrop 
(Thermofisher) before a total of 1ug was DNase treated using the TURBO DNA-free™ 
Kit (Thermofisher) as per manufacturer’s instructions. 
 
qRT-PCR for viral load 
Viral loads were quantified using the GoTaq® Probe 1-Step RT-qPCR System 
(Promega). For quantification of SARS-COV-2 the nCOV_N1 primer/probe mix from 
the SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay (IDT) were utilised while the 
standard curve was generated via 10-fold serial dilution of the 2019-nCoV_N_Positive 
Control (IDT) from 106 to 0.1 copies/reaction. The E sgRNA primers and probe have 
been previously described (https://www.nature.com/articles/s41586-020-2196-x) and 
were utilised at 400nM and 200nM respectively. Murine 18S primers and probe 
sequences ere utilsied at 400nM and 200nM respectively. The IAV primers and probe 
sequences are published as part of the CDC IAV detection kit (20403211). The IAV 
reverse genetics plasmid encoding the NS segment was diluted 10-fold from 106 to 
0.1 copies/reaction to serve as a standard curve. The thermal cycling conditions for all 
qRT-PCR reactions were as follows: 1 cycle of 45°C for 15 min and 1 cycle of 95°C 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 minute. The 18s standard was 
generated by the amplification of a fragment of the murine 18S cDNA using the primers 
F: ACCTGGTTGATCCTGCCAGGTAGC and R: GCATGCCAGAGTCTCGTTCG. 
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Similarly, the E sgRNA standard was generated by PCR using the qPCR primers. 
cDNA was generated using the SuperScript IV reverse transcriptase kit (Thermofisher) 
and PCR carried out using Q5® High-Fidelity 2X Master Mix (New England Biolabs) 
as per manufacturer’s instructions. Both PCR products were purified using the 
QIAquick PCR Purification Kit (Qiagen) and serially diluted 10-fold from 1010 to 104 
copies/reaction to form the standard curve. 
 
 
cDNA sequencing with Oxford Nanopore  
cDNA libraries were made starting with 50ng of total RNA which was accurately 
quantified using a Qubit 3.0 fluorometer (Thermofisher) and the Qubit RNA HS Assay 
Kit (Thermofisher). The cDNA was generated using the PCR-cDNA Barcoding (SQK-
PCB109) sequencing kit by Oxford Nanopore Technologies. Multiplexed libraries were 
loaded onto a R9.4.1 flowcell and ran for up to 72 hours on a GridION. The raw 
sequence reads have been submitted to NCBI SRA under bioproject: PRJNA666048. 
 
RNA sequencing bioinformatic analysis 
Multiplexed sequencing reads were basecalled and demultiplexed by guppy. 
Minimap2 was used to index and map reads to the reference genome 
(Mus_musculus.GRCm38.cdna.all.fa) to generate alignment files using the –ax map-
ont -N 100 -p 1.0 parameters 49. Alignment files were sorted and indexed with samtools 
before counting reads using Salmon with the corresponding annotation file 
(Mus_musculus.GRCm38.gtf) from Ensembl using –noErrorModel -l U parameters 
26,50. The edgeR package was used to normalise sequencing libraries and identify 
differentially expressed genes, defined as at least a 2-fold difference from the mock 
infected group (n=5) and a false discovery rate (FDR) less than 0.05 51. Principle 
component Analysis (PCA), volcano plots, heatmaps and Venn diagrams were 
produced in R studio using the following packages: edgeR, ggplot2 and pheatmap. 
Differential gene expression data was used for gene ontology enrichment analysis of 
biological process terms in each group using enrichGO in the ClusterProfiler 
programme in R 52. A q-value cut-off of 0.05 was used with a Benjamini-Hochberg-
FDR correction. GOSemSim was used to simplify and remove redundant GO terms 53 
and the top 20 biological processes are presented for each condition.  
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Statistical analysis. Data were analysed using the Prism package (version 5.04 
Graphpad Software). P values were set at 95% confidence interval. A repeated-
measures two-way ANOVA (Bonferroni post-test) was used for time-courses of weight 
loss; two-way ANOVA (Bonferroni post-test) was used for other time-courses; log-rank 
(Mantel-Cox) test was used for survival curves. All differences not specifically stated 
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